

China's New Patent System



Speaker:

Chiang Ling Li, Partner, Tiang & Partners

China's New Patent System

Detailed rules for China's patent linkage system have been issued. The development is a significant one as pharmaceutical companies have urgent deadlines which if they don't meet they would lose their rights.

In essence, under the new patent system, innovation companies can finally stop generics from obtaining

market authorisation before patent expiration. However, to obtain such protection, innovation companies must notify the Chinese drug authority of their patents within 30 days of their products obtaining market authorisation. In addition, and in light of the new patent system, generic companies would likely apply to invalidate such patents of innovation companies. Hence, innovation companies need to prepare to defend against invalidation attacks without delay.

China has also reformed other rules relating to pharmaceuticals, biotech and medical devices, including rules relating to clinical trial data.

During this webinar, Chiang Ling Li from Tiang & Partners, will provide insights on the opportunities offered by the new developments in China as well as identify the risks and pain points so that the life sciences industry can address and adopt countermeasures in advance.

Remarks: Hong Kong Law Society CPD points applied for.

About the speaker



Chiang Ling Li is a Partner and the Head of Intellectual Property at Tiang & Partners. Chiang's practice has focused on China IP and pharmaceutical law since 1994. She has been in the forefront of the law, leading successful litigation involving patents, trade secrets, copyright, unfair competition, 3-D marks and well-known marks, as well as successfully pursuing criminal enforcement of IP infringement in China. Chiang works closely with industry organizations lobbying for legal reforms, including those concerning patent linkage and data exclusivity, and has been appointed an

arbitrator by CIETAC, HKIAC, ADNDRC, and the WIPO Arbitration and Mediation Center.

Chiang is author of China Executive Report: Intellectual Property, the China IP chapters of LexisNexis's Intellectual Property Rights, the "Anticounterfeiting and Enforcement" chapter in China's Participation in the WTO, and the China chapters in PLC Cross-border Life Sciences (2007-2012 editions), Trade Secrets Throughout the World Treatise, Patents Throughout the World, and Designs and Utility Models Throughout the World. She is also author of many articles on China IP and pharmaceutical law and practice.

Chiang was among the "A-List" of the top 100 lawyers for China (China Business Law Journal). She is also a PLC recommended lawyer in all three categories of life sciences: intellectual property, corporate and commercial (China), and corporate and commercial. Chiang also has been recognized by The International Who's Who of Life Sciences Lawyers, World Trademark Review (WTR 1000), Chambers Asia-Pacific and Chambers Global, The International Who's Who of Life Sciences Lawyers, The International Who's Who of Business Lawyers, IAM 1000 — The World's Leading Patent Professionals, WTR 1000 — The World's Leading Trademark Professionals, and IAM Licensing 250: The World's Leading Patent and Technology Licensing Practitioners.

Pricing

- Member: HK\$140
- Non-Member: HK\$250

Details on how to join will be sent via email by 5pm the day before the webinar.

Terms & Conditions

- Reservations in advance are required. Please consider your booking confirmed unless notified otherwise.
- Cancellations must be made in writing 24 hours prior to the event. No shows will be charged.
- This event is closed to the media.
- The event will be cancelled if the No.8 Typhoon signal or the Black Rain Storm warning is in force.
- By attending this event, you agree to be photographed, recorded, and/or filmed and give permission to use your likeness in promotional and/or marketing materials.
- For further information please email catherine@britcham.com
- All payments for this event need to be settled by

credit card through PayPal. Please note you do not need a PayPal account to complete payment.